Compare DGII & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | NVCR |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1995 | 2015 |
| Metric | DGII | NVCR |
|---|---|---|
| Price | $52.21 | $10.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $48.80 | $28.08 |
| AVG Volume (30 Days) | 246.9K | ★ 1.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | 21.79 |
| EPS | ★ 0.31 | N/A |
| Revenue | $430,221,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $18.71 | $7.72 |
| Revenue Next Year | $7.22 | $6.74 |
| P/E Ratio | $163.13 | ★ N/A |
| Revenue Growth | 1.46 | ★ 8.28 |
| 52 Week Low | $22.95 | $9.82 |
| 52 Week High | $51.78 | $20.05 |
| Indicator | DGII | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 35.32 |
| Support Level | $47.00 | N/A |
| Resistance Level | N/A | $14.11 |
| Average True Range (ATR) | 1.70 | 0.54 |
| MACD | 0.14 | -0.14 |
| Stochastic Oscillator | 93.93 | 3.13 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.